As monotherapy for patients w/ metastatic breast cancer, where there is an increased cardiac risk. Treatment of metastatic breast cancer in women for whom an anthracycline would be considered or who have failed a taxane-containing regimen. Treatment of advanced ovarian cancer in women who have failed a 1st-line platinum-based chemotherapy regimen. In combination w/ bortezomib for the treatment of progressive multiple myeloma in patients who have received at least 1 prior therapy & who have already undergone or are unsuitable for bone marrow transplant. AIDS-related Kaposi's sarcoma (KS) in patients w/ low CD4 counts & extensive mucocutaneous or visceral disease. 1st-line systemic chemotherapy or as 2nd-line chemotherapy in AIDS-related KS patients w/ disease that has progressed w/, or who are intolerant to, prior combination systemic chemotherapy comprising of at least 2 of these agents: Vinca alkaloid, bleomycin & standard doxorubicin (or other anthracyclines). Multiple myeloma.